Hexima is a clinical stage biotechnology company developing a new prescription treatment for onychomycosis (fungal nail infection). The $5.5 million private placement completed in September 2020 and the $3 million public offer closed oversubscribed on 1 December 2020. The funds raised in the public offer and private placement will be used to complete a phase IIb clinical trial to assess its lead candidate (HXP124) as a treatment for onychomycosis.
Hexima Chief Executive Officer Michael Aldridge commented on the listing: “As a consequence of securing this funding we now have a very clear pathway to deliver the recently initiated Australian phase IIb clinical trial and beyond that, critically important milestones through to the global phase III clinical program, which is the final stage in the development of this exciting and novel product.”
The ABL team was led by Corporate and M&A Consultant Jane Sheridan with assistance from Lawyer Anna Sandiford and Law Graduate Ryan Taylor. The team advised on Hexima’s private placement, public offer, share sale facility and listing.
Jane Sheridan commented: “We are delighted to have assisted Hexima with this listing. The funds will enable Hexima to continue its important clinical trials that offer the potential for successful commercialisation.”
About Arnold Bloch Leibler
Arnold Bloch Leibler is a premium Australian commercial law firm renowned for advising clients on their most important transactions, commercial issues and disputes. From offices in Melbourne and Sydney, the firm provides advice to a diverse range of entrepreneurial Australian listed companies, family businesses, high-net-worth individuals and international corporations. The firm also has a dedicated pro bono practice providing advice on social, environmental and cultural issues to more than 150 charitable and not-for-profit organisations.
